Health Care [ 3/12 ] | Biotechnology [ 26/73 ]
NASDAQ | Common Stock
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.
Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis.
The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma.
It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas.
The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product.
The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.
Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 21, 25 | -0.16 Decreased by -1.70 K% | -0.18 Increased by +13.51% |
| May 22, 25 | -0.24 Decreased by -200.00% | -0.34 Increased by +28.36% |
| Mar 27, 25 | -0.16 Decreased by -128.57% | -0.31 Increased by +48.39% |
| Nov 13, 24 | -0.00 Increased by +99.82% | 0.02 Decreased by -101.14% |
| Aug 8, 24 | 0.01 Increased by +110.00% | -0.15 Increased by +106.67% |
| May 9, 24 | -0.08 Increased by +27.27% | -0.15 Increased by +46.67% |
| Mar 25, 24 | -0.07 Decreased by -187.50% | -0.17 Increased by +58.82% |
| Nov 8, 23 | -0.11 Increased by +72.50% | -0.17 Increased by +35.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by -100.00% | -5.74 M Decreased by -1.33 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -8.65 M Decreased by -216.53% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 4.39 M Decreased by -52.32% | -5.79 M Decreased by -147.40% | Decreased by -131.92% Decreased by -418.84% |
| Sep 30, 24 | 12.16 M Increased by +37.10% | -7.00 K Increased by +99.81% | Decreased by -0.06% Increased by +99.86% |
| Jun 30, 24 | 13.85 M Increased by +51.83% | 468.00 K Increased by +114.00% | Increased by +3.38% Increased by +109.22% |
| Mar 31, 24 | 10.69 M Increased by +20.39% | -2.73 M Increased by +30.61% | Decreased by -25.58% Increased by +42.36% |
| Dec 31, 23 | 9.21 M Decreased by -41.55% | -2.34 M Decreased by -161.52% | Decreased by -25.43% Decreased by -205.25% |
| Sep 30, 23 | 8.87 M Increased by +N/A% | -3.71 M Increased by +72.83% | Decreased by -41.83% Decreased by N/A% |